Gingival enlargement is one of the side effects associated with certain drugs. Amlodipine, a calcium channel blocker, used as antihypertensive drug has been found associated with gingival hyperplasia. This case series presents diagnosis and management of amlodipine-induced gingival hyperplasia. Amlodipine-induced gingival enlargement was diagnosed and managed by thorough scaling and root planning. Drug substitution and surgical intervention was performed in first two cases. The pathogenesis of gingival enlargement is uncertain and the treatment is still largely limited to the maintenance of an improved level of oral hygiene and surgical removal of the overgrown tissue. Several factors may influence the relationship between the drugs and gingival tissues as discussed by Seymour et al. Meticulous oral hygiene maintenance, switchover to alternative drug, professional scaling and root planning and surgical excision of enlarged gingival tissue may help overcome the effect of these drugs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118083PMC
http://dx.doi.org/10.4103/0972-124X.76931DOI Listing

Publication Analysis

Top Keywords

gingival enlargement
16
amlodipine-induced gingival
12
management amlodipine-induced
8
gingival
8
gingival hyperplasia
8
scaling root
8
root planning
8
oral hygiene
8
enlargement
4
enlargement series
4

Similar Publications

Gingival enlargements are mostly plaque-induced. Other than plaque, a few genetic conditions also cause enlargements of the gingiva. In recent years, there has been a notable rise in drug-induced gingival overgrowth (DIGO) linked to the increased use of medications for various systemic conditions.

View Article and Find Full Text PDF

: Although BRAF inhibitors, such as vemurafenib, produce a marked response in patients with advanced melanoma with a BRAF V600 mutation, they eventually develop resistance to this treatment. To address this issue, vemurafenib is increasingly combined with the MEK inhibitor cobimetinib, leading to improved response rates and enhanced survival. However, this treatment modality is associated with numerous side effects.

View Article and Find Full Text PDF

Objectives: Cyclosporine A promotes gingival fibrosis by enhancing the proliferation of gingival fibroblasts, leading to gingival overgrowth. The population of gingival fibroblasts is regulated by cell cycle machinery, which balances cell growth and inhibition. Cells that detect DNA damage pause at the G1/S checkpoint to repair the damage instead of progressing to the S phase.

View Article and Find Full Text PDF

The etiology of diffuse gingival enlargement is multifactorial, and the definitive diagnosis may be challenging. To highlight the nuances of the differential diagnosis, we present two cases of generalized gingival overgrowth and discuss the diagnostic dilemmas. In the first case, an 82-year-old male with a medical history of hypertension and prostatitis had a chief complaint of symptomatic oral lesions of a 20-day duration, accompanied by fever and loss of appetite.

View Article and Find Full Text PDF

Introduction Gingival enlargement (GE) poses a significant problem during fixed orthodontic treatment (FOT). Thus, the primary aim of the current study was to evaluate the concentrations of biomarkers present in the gingival crevicular fluid (GCF) of individuals receiving FOT. The ancillary aim was to examine and compare biomarker levels among patients exhibiting GE undergoing FOT, those without GE undergoing FOT, and a control group comprising individuals not undergoing FOT and to assess the predictors for GE in patients undergoing orthodontic treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!